Skip to main content
Top
Published in: Pediatric Rheumatology 1/2019

Open Access 01-12-2019 | Juvenile Rheumatoid Arthritis | Review

Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review

Authors: Michelle M. A. Kip, Gillian Currie, Deborah A. Marshall, Luiza Grazziotin Lago, Marinka Twilt, Sebastiaan J. Vastert, Joost F. Swart, Nico Wulffraat, Rae S. M. Yeung, Susanne M. Benseler, Maarten J. IJzerman, on behalf of the UCAN CAN-DU Health Economics Working Group

Published in: Pediatric Rheumatology | Issue 1/2019

Login to get access

Abstract

Background

This study aims to describe current practice in identifying and measuring health care resource use and unit costs in economic evaluations or costing studies of juvenile idiopathic arthritis (JIA).

Methods

A scoping review was conducted (in July 2018) in PubMed and Embase to identify economic evaluations, costing studies, or resource utilization studies focusing on patients with JIA. Only English language peer-reviewed articles reporting primary research were included. Data from all included full-text articles were extracted and analysed to identify the reported health care resource use items. In addition, the data sources used to obtain these resource use and unit costs were identified for all included articles.

Results

Of 1176 unique citations identified by the search, 20 full-text articles were included. These involved 4 full economic evaluations, 5 cost-outcome descriptions, 8 cost descriptions, and 3 articles reporting only resource use. The most commonly reported health care resource use items involved medication (80%), outpatient and inpatient hospital visits (80%), laboratory tests (70%), medical professional visits (70%) and other medical visits (65%). Productivity losses of caregivers were much more often incorporated than (future) productivity losses of patients (i.e. 55% vs. 15%). Family borne costs were not commonly captured (ranging from 15% for school costs to 50% for transportation costs). Resource use was mostly obtained from family self-reported questionnaires. Estimates of unit costs were mostly based on reimbursement claims, administrative data, or literature.

Conclusions

Despite some consistency in commonly included health care resource use items, variability remains in including productivity losses, missed school days and family borne costs. As these items likely substantially influence the full cost impact of JIA, the heterogeneity found between the items reported in the included studies limits the comparability of the results. Therefore, standardization of resource use items and unit costs to be collected is required. This standardization will provide guidance to future research and thereby improve the quality and comparability of economic evaluations or costing studies in JIA and potentially other childhood diseases. This would allow better understanding of the burden of JIA, and to estimate how it varies across health care systems.
Appendix
Available only for authorised users
Footnotes
1
The term ‘unit costs’ indicates the mean costs per unit. The total costs per resource use item can be calculated by multiplying the unit costs with the accompanying resource utilization.
 
2
UCAN CAN-DU is the Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic diseases.
 
Literature
1.
go back to reference Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002;29(7):1520–30.PubMed Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002;29(7):1520–30.PubMed
2.
go back to reference Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J. 2010;8:20.CrossRef Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J. 2010;8:20.CrossRef
3.
go back to reference Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.CrossRef Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.CrossRef
4.
go back to reference Ringold S, Ward TM, Wallace CA. Disease activity and fatigue in juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(3):391–7.CrossRef Ringold S, Ward TM, Wallace CA. Disease activity and fatigue in juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(3):391–7.CrossRef
5.
go back to reference Armbrust W, Lelieveld OH, Tuinstra J, Wulffraat NM, Bos GJ, Cappon J, et al. Fatigue in patients with juvenile idiopathic arthritis: relationship to perceived health, physical health, self-efficacy, and participation. Pediatr Rheumatol Online J. 2016;14(1):65.CrossRef Armbrust W, Lelieveld OH, Tuinstra J, Wulffraat NM, Bos GJ, Cappon J, et al. Fatigue in patients with juvenile idiopathic arthritis: relationship to perceived health, physical health, self-efficacy, and participation. Pediatr Rheumatol Online J. 2016;14(1):65.CrossRef
6.
go back to reference Muller-Godeffroy E, Lehmann H, Kuster RM, Thyen U. Quality of life and psychosocial adaptation in children and adolescents with juvenile idiopathic arthritis and reactive arthritis. Z Rheumatol. 2005;64(3):177–87.CrossRef Muller-Godeffroy E, Lehmann H, Kuster RM, Thyen U. Quality of life and psychosocial adaptation in children and adolescents with juvenile idiopathic arthritis and reactive arthritis. Z Rheumatol. 2005;64(3):177–87.CrossRef
7.
go back to reference Mullick MS, Nahar JS, Haq SA. Psychiatric morbidity, stressors, impact, and burden in juvenile idiopathic arthritis. J Health Popul Nutr. 2005;23(2):142–9.PubMed Mullick MS, Nahar JS, Haq SA. Psychiatric morbidity, stressors, impact, and burden in juvenile idiopathic arthritis. J Health Popul Nutr. 2005;23(2):142–9.PubMed
8.
go back to reference Bouaddi I, Rostom S, El Badri D, Hassani A, Chkirate B, Amine B, et al. Impact of juvenile idiopathic arthritis on schooling. BMC Pediatr. 2013;13:2.CrossRef Bouaddi I, Rostom S, El Badri D, Hassani A, Chkirate B, Amine B, et al. Impact of juvenile idiopathic arthritis on schooling. BMC Pediatr. 2013;13:2.CrossRef
9.
go back to reference Kuhlmann A, Schmidt T, Treskova M, Lopez-Bastida J, Linertova R, Oliva-Moreno J, et al. Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ. 2016;17(Suppl 1):79–87.CrossRef Kuhlmann A, Schmidt T, Treskova M, Lopez-Bastida J, Linertova R, Oliva-Moreno J, et al. Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ. 2016;17(Suppl 1):79–87.CrossRef
10.
go back to reference Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.CrossRef Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.CrossRef
11.
go back to reference Prince FH, van Suijlekom-Smit LW. Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked. Paediatr Drugs. 2013;15(4):271–80.CrossRef Prince FH, van Suijlekom-Smit LW. Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked. Paediatr Drugs. 2013;15(4):271–80.CrossRef
12.
go back to reference Flato B, Aasland A, Vinje O, Forre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol. 1998;25(2):366–75.PubMed Flato B, Aasland A, Vinje O, Forre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol. 1998;25(2):366–75.PubMed
13.
go back to reference Schlichtiger J, Haas JP, Barth S, Bisdorff B, Hager L, Michels H, et al. Education and employment in patients with juvenile idiopathic arthritis - a standardized comparison to the German general population. Pediatr Rheumatol Online J. 2017;15(1):45.CrossRef Schlichtiger J, Haas JP, Barth S, Bisdorff B, Hager L, Michels H, et al. Education and employment in patients with juvenile idiopathic arthritis - a standardized comparison to the German general population. Pediatr Rheumatol Online J. 2017;15(1):45.CrossRef
14.
go back to reference Barth S, Haas JP, Schlichtiger J, Molz J, Bisdorff B, Michels H, et al. Long-term health-related quality of life in German patients with juvenile idiopathic arthritis in comparison to German general population. PLoS One. 2016;11(4):e0153267.CrossRef Barth S, Haas JP, Schlichtiger J, Molz J, Bisdorff B, Michels H, et al. Long-term health-related quality of life in German patients with juvenile idiopathic arthritis in comparison to German general population. PLoS One. 2016;11(4):e0153267.CrossRef
15.
go back to reference Tollisen A, Selvaag AM, Aulie HA, Lilleby V, Aasland A, Lerdal A, et al. Physical functioning, pain and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year follow-up study. Arthritis Care Res. 2018;70(5):741–749CrossRef Tollisen A, Selvaag AM, Aulie HA, Lilleby V, Aasland A, Lerdal A, et al. Physical functioning, pain and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year follow-up study. Arthritis Care Res. 2018;70(5):741–749CrossRef
16.
go back to reference Drummond MF, Sculpher MJ, Claxton K, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. p. 404. Drummond MF, Sculpher MJ, Claxton K, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. p. 404.
17.
go back to reference CADTH. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. CADTH. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
19.
go back to reference CADTH. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017. CADTH. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
20.
go back to reference Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.CrossRef Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.CrossRef
21.
go back to reference Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016. Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016.
22.
go back to reference Thorn JC, Brookes ST, Ridyard C, Riley R, Hughes DA, Wordsworth S, et al. Core items for a standardized resource use measure: expert Delphi consensus survey. Value Health. 2018;21(6):640–9.CrossRef Thorn JC, Brookes ST, Ridyard C, Riley R, Hughes DA, Wordsworth S, et al. Core items for a standardized resource use measure: expert Delphi consensus survey. Value Health. 2018;21(6):640–9.CrossRef
23.
go back to reference Leggett LE, Khadaroo RG, Holroyd-Leduc J, Lorenzetti DL, Hanson H, Wagg A, et al. Measuring resource utilization: a systematic review of validated self-reported questionnaires. Medicine (Baltimore). 2016;95(10):e2759.CrossRef Leggett LE, Khadaroo RG, Holroyd-Leduc J, Lorenzetti DL, Hanson H, Wagg A, et al. Measuring resource utilization: a systematic review of validated self-reported questionnaires. Medicine (Baltimore). 2016;95(10):e2759.CrossRef
24.
go back to reference Noben CY, de Rijk A, Nijhuis F, Kottner J, Evers S. The exchangeability of self-reports and administrative health care resource use measurements: assessement of the methodological reporting quality. J Clin Epidemiol. 2016;74:93–106 e2.CrossRef Noben CY, de Rijk A, Nijhuis F, Kottner J, Evers S. The exchangeability of self-reports and administrative health care resource use measurements: assessement of the methodological reporting quality. J Clin Epidemiol. 2016;74:93–106 e2.CrossRef
26.
go back to reference Arksey H, O'malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef Arksey H, O'malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef
27.
go back to reference Mays N, Roberts E, Popay J. Synthesising research evidence. In: N. Fulop, P. Allen, A. Clarke, N. Black, editors. Methods for studying the delivery and organisation of health services. London: Routledge; 2001. Mays N, Roberts E, Popay J. Synthesising research evidence. In: N. Fulop, P. Allen, A. Clarke, N. Black, editors. Methods for studying the delivery and organisation of health services. London: Routledge; 2001.
29.
go back to reference Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964–79.CrossRef Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964–79.CrossRef
30.
go back to reference Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17(5):31.CrossRef Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17(5):31.CrossRef
31.
go back to reference Minden K. What are the costs of childhood-onset rheumatic disease? Best Pract Res Clin Rheumatol. 2006;20(2):223–40.CrossRef Minden K. What are the costs of childhood-onset rheumatic disease? Best Pract Res Clin Rheumatol. 2006;20(2):223–40.CrossRef
32.
go back to reference Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222.CrossRef Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222.CrossRef
33.
go back to reference Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19(6):952–5.PubMed Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19(6):952–5.PubMed
34.
go back to reference Angelis A, Kanavos P, Lopez-Bastida J, Linertova R, Serrano-Aguilar P, B-RR N. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom. BMC Musculoskelet Disord. 2016;17:321.CrossRef Angelis A, Kanavos P, Lopez-Bastida J, Linertova R, Serrano-Aguilar P, B-RR N. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom. BMC Musculoskelet Disord. 2016;17:321.CrossRef
35.
go back to reference Toupin-April K, Feldman DE, Zunzunegui MV, Descarreaux M, Malleson P, Duffy CM. Longitudinal analysis of complementary and alternative health care use in children with juvenile idiopathic arthritis. Complement Ther Med. 2009;17(4):208–15.CrossRef Toupin-April K, Feldman DE, Zunzunegui MV, Descarreaux M, Malleson P, Duffy CM. Longitudinal analysis of complementary and alternative health care use in children with juvenile idiopathic arthritis. Complement Ther Med. 2009;17(4):208–15.CrossRef
36.
go back to reference Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(1):44–8.CrossRef Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(1):44–8.CrossRef
37.
go back to reference Ens A, Lang B, Ramsey S, Stringer E, Huber AM. The financial burden of juvenile idiopathic arthritis: a Nova Scotia experience. Pediatr Rheumatol Online J. 2013;11(1):24.CrossRef Ens A, Lang B, Ramsey S, Stringer E, Huber AM. The financial burden of juvenile idiopathic arthritis: a Nova Scotia experience. Pediatr Rheumatol Online J. 2013;11(1):24.CrossRef
38.
go back to reference Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess. 2005;9(39):iii–v ix-x, 1-59.CrossRef Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess. 2005;9(39):iii–v ix-x, 1-59.CrossRef
39.
go back to reference Haapasaari J, Kautiainen HJ, Isomaki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286–9.PubMed Haapasaari J, Kautiainen HJ, Isomaki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286–9.PubMed
40.
go back to reference Luca NJ, Burnett HF, Ungar WJ, Moretti ME, Beukelman T, Feldman BM, et al. Cost-effectiveness analysis of first-line treatment with biologic agents in Polyarticular juvenile idiopathic arthritis. Arthritis Care Res. 2016;68(12):1803–11.CrossRef Luca NJ, Burnett HF, Ungar WJ, Moretti ME, Beukelman T, Feldman BM, et al. Cost-effectiveness analysis of first-line treatment with biologic agents in Polyarticular juvenile idiopathic arthritis. Arthritis Care Res. 2016;68(12):1803–11.CrossRef
41.
go back to reference Minden K, Niewerth M, Listing J, Biedermann T, Schontube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(7):836–42.CrossRef Minden K, Niewerth M, Listing J, Biedermann T, Schontube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(7):836–42.CrossRef
42.
go back to reference Minden K, Niewerth M, Listing J, Mobius D, Thon A, Ganser G, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27(5):863–9.PubMed Minden K, Niewerth M, Listing J, Mobius D, Thon A, Ganser G, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27(5):863–9.PubMed
43.
go back to reference Pohjankoski H, Latva K, Kautiainen H, Saila H, Klaukka T, Virta L, et al. First-year purchases of disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland. Clin Exp Rheumatol. 2011;29(5):878–81.PubMed Pohjankoski H, Latva K, Kautiainen H, Saila H, Klaukka T, Virta L, et al. First-year purchases of disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland. Clin Exp Rheumatol. 2011;29(5):878–81.PubMed
44.
go back to reference Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatology (Oxford). 2011;50(6):1131–6.CrossRef Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatology (Oxford). 2011;50(6):1131–6.CrossRef
45.
go back to reference Rasu RS, Cline SK, Shaw JW, Hayes O, Bawa WA, Cifaldi MA. Impact of JIA on parents’ work absences. Rheumatology. 2015;54(7):1177–85.CrossRef Rasu RS, Cline SK, Shaw JW, Hayes O, Bawa WA, Cifaldi MA. Impact of JIA on parents’ work absences. Rheumatology. 2015;54(7):1177–85.CrossRef
46.
go back to reference Seburg EM, Horvath KJ, Garwick AW, McMorris BJ, Vehe RK, Scal P. Complementary and alternative medicine use among youth with juvenile arthritis: are youth using CAM, but not talking about it? J Adolesc Health. 2012;51(2):200–2.CrossRef Seburg EM, Horvath KJ, Garwick AW, McMorris BJ, Vehe RK, Scal P. Complementary and alternative medicine use among youth with juvenile arthritis: are youth using CAM, but not talking about it? J Adolesc Health. 2012;51(2):200–2.CrossRef
47.
go back to reference Thornton J, Ashcroft D, O'Neill T, Elliott R, Adams J, Roberts C, et al. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol Assess. 2008;12(3):iii–x xi-xiv, 1-208.CrossRef Thornton J, Ashcroft D, O'Neill T, Elliott R, Adams J, Roberts C, et al. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol Assess. 2008;12(3):iii–x xi-xiv, 1-208.CrossRef
48.
go back to reference Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology (Oxford). 2008;47(7):985–90.CrossRef Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology (Oxford). 2008;47(7):985–90.CrossRef
49.
go back to reference Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res. 2011;63(1):111–9.CrossRef Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res. 2011;63(1):111–9.CrossRef
50.
go back to reference Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, et al. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clin Exp Rheumatol. 2018;36(5):920–928 Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, et al. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clin Exp Rheumatol. 2018;36(5):920–928
51.
go back to reference Thorn JC, Brookes ST, Ridyard CH, Riley R, Hughes DA, Wordsworth S, et al. Core items for a standardized resource use measure (ISRUM): expert delphi consensus survey. Value in Health 2018;21(6):640–649.CrossRef Thorn JC, Brookes ST, Ridyard CH, Riley R, Hughes DA, Wordsworth S, et al. Core items for a standardized resource use measure (ISRUM): expert delphi consensus survey. Value in Health 2018;21(6):640–649.CrossRef
52.
go back to reference Drummond M, Weatherly H, Ferguson B. Economic evaluation of health interventions. BMJ. 2008;337:a1204.CrossRef Drummond M, Weatherly H, Ferguson B. Economic evaluation of health interventions. BMJ. 2008;337:a1204.CrossRef
53.
go back to reference Drost R, van der Putten IM, Ruwaard D, Evers S, Paulus ATG. Conceptualizations of the societal perspective within economic evaluations: a systematic review. Int J Technol Assess Health Care. 2017;33(2):251–60.CrossRef Drost R, van der Putten IM, Ruwaard D, Evers S, Paulus ATG. Conceptualizations of the societal perspective within economic evaluations: a systematic review. Int J Technol Assess Health Care. 2017;33(2):251–60.CrossRef
54.
go back to reference Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010;13(1):8–13.CrossRef Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010;13(1):8–13.CrossRef
Metadata
Title
Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review
Authors
Michelle M. A. Kip
Gillian Currie
Deborah A. Marshall
Luiza Grazziotin Lago
Marinka Twilt
Sebastiaan J. Vastert
Joost F. Swart
Nico Wulffraat
Rae S. M. Yeung
Susanne M. Benseler
Maarten J. IJzerman
on behalf of the UCAN CAN-DU Health Economics Working Group
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2019
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-019-0321-x

Other articles of this Issue 1/2019

Pediatric Rheumatology 1/2019 Go to the issue